BeyondSpring (BYSI) Change in Accured Expenses (2016 - 2026)
BeyondSpring (BYSI) posted Change in Accured Expenses of -$1.4 million for Q1 2026, down 373.53% sequentially from $510000.0 in Q4 2025, and down 269.09% YoY from $825000.0 in Q1 2025.
BeyondSpring (BYSI) Change in Accured Expenses (2016 - 2026) Analysis & Trends
BeyondSpring has reported Change in Accured Expenses for 9 years, with the latest figure at -$1.4 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 269.09% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$378000.0 (down 121.9% YoY) and the FY2025 annual result came in at $1.8 million, up 575.97% from the prior year.
- Change in Accured Expenses fell to -$1.4 million in Q1 2026 per BYSI's latest filing, from $510000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $825000.0 in Q1 2025 and troughed at -$1.4 million in Q1 2026.
- A 3-year average of $6666.7 and a median of $417000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses jumped 886.79% in 2025, then plunged 269.09% in 2026.
- Over 3 years, Change in Accured Expenses stood at $493000.0 in 2024, then grew by 3.45% to $510000.0 in 2025, then sank by 373.53% to -$1.4 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.4 million, $510000.0, and $417000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | 2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.11 Mn |
| Jun 30, 2026 | 2.11 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | 510,000.00 |
| Dec 31, 2025 | 510,000.00 |
| Sep 30, 2025 | 417,000.00 |
| Sep 30, 2025 | 417,000.00 |
| Jun 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 90,000.00 |
| Mar 31, 2025 | 825,000.00 |
| Mar 31, 2025 | 825,000.00 |
| Dec 31, 2024 | 493,000.00 |
| Dec 31, 2024 | 493,000.00 |
| Sep 30, 2024 | -53,000.00 |
| Sep 30, 2024 | -53,000.00 |
| Jun 30, 2024 | 461,000.00 |
| Jun 30, 2024 | 461,000.00 |
| Mar 31, 2024 | -1.29 Mn |
| Mar 31, 2024 | -1.29 Mn |